|
|
|
| Targeting pancreatic ductal adenocarcinoma: New therapeutic options
for the ongoing battle |
| Pratibha Malhotra, Ranjith Palanisamy, Marco Falasca ∗ |
Metabolic Signalling Group, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, 6102, Australia
∗ Corresponding author.
E-mail address: marco.falasca@curtin.edu.au (M. Falasca). |
|
|
|
|
Abstract Pancreatic ductal adenocarcinoma (PDAC), the most commonly reported form of pancreatic cancer, is a lethal malignancy that contributes to the global cancer burden with high morbidity and mortality [1]. It has a poor 5-year survival mainly because PDAC poses a significant diagnostic challenge, has a high metastatic rate at diagnosis and is stubbornly resistant to therapy [2].
|
|
|
|
|
|
|
|
|
2022, Vol. 21 
